IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about General Updates
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product Metformin Hydrochloride (Process-II), granted on 5th March 2026. This is an additional CEP — the company already holds a valid CEP for Metformin Hydrochloride under a different process. Metformin is a widely used antidiabetic medication for managing high blood sugar in diabetes patients. The CEP is a regulatory clearance required to market an API in European markets.
This strengthens IOL's regulatory standing in Europe for a high-volume diabetes API and gives European customers a second approved process to source from, which could support export volumes and pricing power. Positive for the stock on regulatory progress, though no immediate revenue numbers are disclosed.